- Home
- IIF vs EDIT Comparison
IIF vs EDIT Comparison
Compare IIF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIF
- EDIT
- Stock Information
- Founded
- IIF 1993
- EDIT 2013
- Country
- IIF United States
- EDIT United States
- Employees
- IIF N/A
- EDIT N/A
- Industry
- IIF Trusts Except Educational Religious and Charitable
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IIF Finance
- EDIT Health Care
- Exchange
- IIF Nasdaq
- EDIT Nasdaq
- Market Cap
- IIF 254.6M
- EDIT 269.8M
- IPO Year
- IIF N/A
- EDIT 2016
- Fundamental
- Price
- IIF $27.80
- EDIT $3.17
- Analyst Decision
- IIF
- EDIT Buy
- Analyst Count
- IIF 0
- EDIT 11
- Target Price
- IIF N/A
- EDIT $4.56
- AVG Volume (30 Days)
- IIF 45.4K
- EDIT 3.2M
- Earning Date
- IIF 01-01-0001
- EDIT 10-31-2025
- Dividend Yield
- IIF 13.94%
- EDIT N/A
- EPS Growth
- IIF N/A
- EDIT N/A
- EPS
- IIF N/A
- EDIT N/A
- Revenue
- IIF N/A
- EDIT $38,901,000.00
- Revenue This Year
- IIF N/A
- EDIT N/A
- Revenue Next Year
- IIF N/A
- EDIT N/A
- P/E Ratio
- IIF N/A
- EDIT N/A
- Revenue Growth
- IIF N/A
- EDIT N/A
- 52 Week Low
- IIF $18.95
- EDIT $0.91
- 52 Week High
- IIF $24.41
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- IIF 66.96
- EDIT 42.68
- Support Level
- IIF $27.29
- EDIT $3.48
- Resistance Level
- IIF $27.80
- EDIT $3.87
- Average True Range (ATR)
- IIF 0.37
- EDIT 0.35
- MACD
- IIF 0.10
- EDIT -0.11
- Stochastic Oscillator
- IIF 91.03
- EDIT 4.92
About IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.